Corcept Therapeutics Announces Results From CATALYST Clinical Trial At ADA's 84th Scientific Sessions; Study Shows 24% Prevalence Of Hypercortisolism In Patients With Difficult-To-Control Type 2 Diabetes; Largest Study To Date With 1,055 Patients
Portfolio Pulse from Benzinga Newsdesk
Corcept Therapeutics announced results from the CATALYST clinical trial at the ADA's 84th Scientific Sessions, showing a 24% prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes. The study, involving 1,055 patients, is the largest of its kind.
June 24, 2024 | 8:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Corcept Therapeutics presented significant findings from the CATALYST clinical trial, showing a 24% prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes. This could lead to increased interest and potential demand for Corcept's treatments.
The positive results from the CATALYST trial highlight a significant medical need that Corcept Therapeutics can address, potentially increasing demand for their treatments and positively impacting their stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100